ArticleMolecular biology reports2026
Nortriptyline exerts context-dependent cytokine modulation and reduces pHrodo-associated phagocytic response in activated J774.2 macrophages.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMajor depressive disorder is frequently associated with immune-inflammatory activation that influences treatment outcomes. Although tricyclic antidepressants like nortriptyline are extensively utilized for depression and neuropathic pain management, their direct immunomodulatory effects on core innate immune executors require further characterization. Therefore, this study evaluated the condition-dependent immunomodulatory activities of nortriptyline by assessing its integrated effects on pro-inflammatory cytokine secretion and functional phagocytic capacity in J774.2 murine macrophages.
methodsCells were treated with non-cytotoxic concentrations of nortriptyline (1, 3, and 5 µg/mL) under basal or Lipopolysaccharide (LPS, 1 µg/mL)-stimulated conditions. Extracellular secretion profiles of TNF-α, IL-12p40, IL-6, and GM-CSF were quantified via ELISA, while the functional phagocytic response was evaluated using fluorogenic pHrodo™ Green E. coli BioParticles™ via flow cytometry.
resultsNortriptyline sustained cellular viability above 85% across all evaluated concentrations (1, 3, and 5 µg/mL). Under LPS challenge, nortriptyline drove a highly distinct, cytokine-specific regulatory trajectory, showing a numerical concentration-dependent downward trend in TNF-α (down to ~ 6,342 pg/mL, P > 0.05) and a significant concentration-dependent suppression of IL-12p40 (down to ~ 5,767 pg/mL, P < 0.01). Regarding IL-6 levels, low-dose (1 µg/mL) nortriptyline co-treatment resulted in a higher IL-6 secretion compared to LPS alone (~ 5,700 pg/mL), whereas the maximum dose (5 µg/mL) significantly diminished its secretion to ~ 3,100 pg/mL relative to the LPS control. Functionally, 5 µg/mL nortriptyline significantly reduced the pHrodo-associated phagocytic response, decreasing the proportion of active effector cells from 77% down to 45%.
conclusionThese findings demonstrate that nortriptyline exerts context-dependent cytokine modulation and reduces pHrodo-associated phagocytic response in J774.2 murine macrophages, highlighting the direct capacity of this tricyclic compound to alter specific innate inflammatory outputs in vitro.
Indexed as
Identifiers
42667302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.